UNSPSC 51385200: Nonsteroidal anti inflammatory quinazolines

Nonsteroidal anti inflammatory drugs made of benzopyrimidines, or compounds consisting of two six-membered rings, one benzene, one pyrimidine ring.

UNSPSC 51385200 Nonsteroidal anti inflammatory quinazolines is a Class code that in recent state and local procurement activity covers the supply of pharmaceutical products and related health-system commodities — though the recent opportunities tagged to this code diverge significantly from the nominal code name and include naloxone distribution systems, generic multi-source pharmaceuticals through cooperative purchasing, and direct-to-manufacturer pharmacy benefit initiatives rather than quinazolines specifically. State and local issuing bodies purchasing under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Department of Administration (administering the Minnesota Multistate Cooperative Purchasing Alliance) appear among recent buyers.

Activity concentrates in Florida, Texas, and Minnesota. The most recent solicitations include Seminole County's IFB60459723LAS, an IFB posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023; the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, requesting vendor capabilities and market intelligence for a direct-to-manufacturer prescription program; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802, posted January 20, 2026, with a March 26, 2026 response deadline, establishing multiple contracts for generic multi-source pharmaceuticals and over-the-counter products across participating state and local facilities. The MMCAP procurement requires vendors to work through three authorized wholesalers and specifies weighted evaluation criteria favoring price competitiveness (75 percent), with products effective July 1, 2026. These opportunities suggest active procurement for pharmaceutical supply chains and health system distribution, though the code's recent tagging appears to span a broader pharmaceutical-product family than the quinazolines category name implies.